Cargando…
Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects
BACKGROUND: Ketosis-prone diabetes (KPDM) is new-onset diabetic ketoacidosis without precipitating factors in non-type 1 diabetic patients; after management, some are withdrawn from exogenous insulin, although determining factors remain unclear. METHODS: Twenty KPDM patients and twelve type 1 diabet...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183552/ https://www.ncbi.nlm.nih.gov/pubmed/25275325 http://dx.doi.org/10.1371/journal.pone.0109237 |
_version_ | 1782337711651160064 |
---|---|
author | Liu, Yan Gupta, Priyanka Lapointe, Marc Yotsapon, Thewjitcharoen Sarat, Sunthornyothin Cianflone, Katherine |
author_facet | Liu, Yan Gupta, Priyanka Lapointe, Marc Yotsapon, Thewjitcharoen Sarat, Sunthornyothin Cianflone, Katherine |
author_sort | Liu, Yan |
collection | PubMed |
description | BACKGROUND: Ketosis-prone diabetes (KPDM) is new-onset diabetic ketoacidosis without precipitating factors in non-type 1 diabetic patients; after management, some are withdrawn from exogenous insulin, although determining factors remain unclear. METHODS: Twenty KPDM patients and twelve type 1 diabetic patients (T1DM), evaluated at baseline, 12 and 24 months with/without insulin maintenance underwent a standardized mixed-meal tolerance test (MMTT) for 2 h. RESULTS: At baseline, triglyceride and C3 were higher during MMTT in KPDM vs. T1DM (p<0.0001) with no differences in non-esterified fatty acids (NEFA) while Acylation Stimulating Protein (ASP) tended to be higher. Within 12 months, 11 KPDM were withdrawn from insulin treatment (KPDM-ins), while 9 were maintained (KPDM+ins). NEFA was lower in KPDM-ins vs. KPDM+ins at baseline (p = 0.0006), 12 months (p<0.0001) and 24 months (p<0.0001) during MMTT. NEFA in KPDM-ins decreased over 30–120 minutes (p<0.05), but not in KPDM+ins. Overall, C3 was higher in KPDM-ins vs KPDM+ins at 12 months (p = 0.0081) and 24 months (p = 0.0019), while ASP was lower at baseline (p = 0.0024) and 12 months (p = 0.0281), with a decrease in ASP/C3 ratio. CONCLUSIONS: Notwithstanding greater adiposity in KPDM-ins, greater NEFA decreases and lower ASP levels during MMTT suggest better insulin and ASP sensitivity in these patients. |
format | Online Article Text |
id | pubmed-4183552 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-41835522014-10-07 Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects Liu, Yan Gupta, Priyanka Lapointe, Marc Yotsapon, Thewjitcharoen Sarat, Sunthornyothin Cianflone, Katherine PLoS One Research Article BACKGROUND: Ketosis-prone diabetes (KPDM) is new-onset diabetic ketoacidosis without precipitating factors in non-type 1 diabetic patients; after management, some are withdrawn from exogenous insulin, although determining factors remain unclear. METHODS: Twenty KPDM patients and twelve type 1 diabetic patients (T1DM), evaluated at baseline, 12 and 24 months with/without insulin maintenance underwent a standardized mixed-meal tolerance test (MMTT) for 2 h. RESULTS: At baseline, triglyceride and C3 were higher during MMTT in KPDM vs. T1DM (p<0.0001) with no differences in non-esterified fatty acids (NEFA) while Acylation Stimulating Protein (ASP) tended to be higher. Within 12 months, 11 KPDM were withdrawn from insulin treatment (KPDM-ins), while 9 were maintained (KPDM+ins). NEFA was lower in KPDM-ins vs. KPDM+ins at baseline (p = 0.0006), 12 months (p<0.0001) and 24 months (p<0.0001) during MMTT. NEFA in KPDM-ins decreased over 30–120 minutes (p<0.05), but not in KPDM+ins. Overall, C3 was higher in KPDM-ins vs KPDM+ins at 12 months (p = 0.0081) and 24 months (p = 0.0019), while ASP was lower at baseline (p = 0.0024) and 12 months (p = 0.0281), with a decrease in ASP/C3 ratio. CONCLUSIONS: Notwithstanding greater adiposity in KPDM-ins, greater NEFA decreases and lower ASP levels during MMTT suggest better insulin and ASP sensitivity in these patients. Public Library of Science 2014-10-02 /pmc/articles/PMC4183552/ /pubmed/25275325 http://dx.doi.org/10.1371/journal.pone.0109237 Text en © 2014 Liu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Liu, Yan Gupta, Priyanka Lapointe, Marc Yotsapon, Thewjitcharoen Sarat, Sunthornyothin Cianflone, Katherine Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects |
title | Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects |
title_full | Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects |
title_fullStr | Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects |
title_full_unstemmed | Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects |
title_short | Acylation Stimulating Protein, Complement C3 and Lipid Metabolism in Ketosis-Prone Diabetic Subjects |
title_sort | acylation stimulating protein, complement c3 and lipid metabolism in ketosis-prone diabetic subjects |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183552/ https://www.ncbi.nlm.nih.gov/pubmed/25275325 http://dx.doi.org/10.1371/journal.pone.0109237 |
work_keys_str_mv | AT liuyan acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects AT guptapriyanka acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects AT lapointemarc acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects AT yotsaponthewjitcharoen acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects AT saratsunthornyothin acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects AT cianflonekatherine acylationstimulatingproteincomplementc3andlipidmetabolisminketosispronediabeticsubjects |